Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine

References

• American Academy of Pediatrics, Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011;128:1007-22
   PubMed Web of Science ®Google Scholar
• Polanczyk GV, Salum GA, Sugaya LS, et al. Annual research review: a meta-analysis of the worldwide prevalence of mental disorders in children and adolescents. J Child Psychol Psychiatry 2015;56:345-65
   PubMed Web of Science ®Google Scholar
• Štuhec M, Švab V, Locatelli I. Prevalence and incidence of attention-deficit/hyperactivity disorder in Slovenian children and adolescents: a database study from a national perspective. Croat Med J 2015;56:159-65
   PubMed Web of Science ®Google Scholar
• Stuhec M, Locatelli I. Age-related pharmacotherapy of attention deficit hyperactivity disorder in Slovenia in children and adolescents: a population-based study. Eur Psychiatry 2017;42:129-33
   PubMed Web of Science ®Google Scholar
• Visser SN, Danielson ML, Bitsko RH, et al. Trends in the parent-report of health care provider-diagnosed and medicated ADHD: United States, 2003–2011. J Am Acad Child Adolesc Psychiatry 2014;53:34-46.e2
   PubMed Web of Science ®Google Scholar
• Barkley RA, Fischer M, Smallish L, et al. Young adult follow-up of hyperactive children: antisocial activities and medication use. J Child Psychol Psychiatry 2004;45:195-211
   PubMed Web of Science ®Google Scholar
• Hodgkins P, Montejano L, Sasane R, et al. Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysis. Prim Care Companion CNS Disord 2011;13
   Google Scholar
• Meyers J, Classi P, Wietecha L, et al. Economic burden and comorbidities of attention-deficit/hyperactivity disorder among pediatric patients hospitalized in the United States. Child Adolesc Psychiatry Mental Health 2010;4:31
   PubMedGoogle Scholar
• Secnik K, Swensen A, Lage MJ. Comorbidities and costs of adult patients diagnosed with attention-deficit hyperactivity disorder. Pharmacoeconomics 2005;23:93-102
   PubMed Web of Science ®Google Scholar
• Doshi JA, Hodgkins P, Kahle J, et al. Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry 2012;51:990-1002.e2
   PubMed Web of Science ®Google Scholar
• Matza LS, Paramore C, Prasad M. A review of the economic burden of ADHD. Cost Eff Resour Alloc 2005;3:5
   PubMedGoogle Scholar
• Leibson CL, Katusic SK, Barbaresi WJ, et al. Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. JAMA 2001;285:60-6
   PubMed Web of Science ®Google Scholar
• Gupte-Singh K, Singh RR, Lawson KA. Economic burden of attention-deficit/hyperactivity disorder among pediatric patients in the United States. Value Health 2017;20:602-9
   PubMed Web of Science ®Google Scholar
• Attention-Deficit/Hyperactivity Disorder (ADHD): treatment [Internet]. Atlanta, GA: Centers for Disease Control and Prevention; 2017. Available online at: https://www.cdc.gov/ncbddd/adhd/treatment.html. Accessed September 15, 2017
   Google Scholar
• Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011;128:1007-22
   PubMed Web of Science ®Google Scholar
• Bolea-Almanac B, Nutt DJ, Adamou M, et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2014;28:179-203
   PubMed Web of Science ®Google Scholar
• Faraone SV. Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. Pharmacy and Therapeutics. 2009;34:678-94
   Google Scholar
• Stuhec M, Munda B, Svab V, et al. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion. J Affect Disord 2015;178:149-59
   PubMed Web of Science ®Google Scholar
• Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009;23(Suppl1):21-31
   Web of Science ®Google Scholar
• Faraone SV, Biederman J Spencer TJ, et al. Comparing the efficacy of medications for ADHD using meta-analysis. MedGenMed 2006;8:4
   PubMedGoogle Scholar
• Hah M, Chang K. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol 2005;15:996-1004
   PubMed Web of Science ®Google Scholar
• Shier AC, Reichenbacher T, Ghuman HS, et al. Pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: clinical strategies. J Cent Nerv Syst Dis 2012;5:1-17
   PubMedGoogle Scholar
• Strattera® [package insert] [Internet]. Indianapolis, IN: Eli Lilly and Company; 2014. Available online at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021411s044lbl.pdf. Accessed September 9, 2017
   Google Scholar
• Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002;27:699-711 [Database]
   PubMed Web of Science ®Google Scholar
• Berridge CW, Devilbiss DM, Andrzejewski ME, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 2006;60:1111-20
   PubMed Web of Science ®Google Scholar
• Easton N, Steward C, Marshall F, et al. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology 2007;52:405-14
   PubMed Web of Science ®Google Scholar
• Michelson D, Faries D, Wernicke J, et al. Atomoxetine ADHD study group. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001;108:E83
   PubMed Web of Science ®Google Scholar
• Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo controlled study. Am J Psychiatry 2002;159:1896-901
   PubMed Web of Science ®Google Scholar
• Wolraich ML, McGuinn L, Doffing M. Treatment of attention deficit hyper-activity disorder in children and adolescents: safety considerations. Drug Saf 2007;30:17-26
   PubMed Web of Science ®Google Scholar
• Intuniv® [package insert] [Internet]. Wayne, PA: Shire Pharmaceuticals; 2013. Available online at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022037s011lbl.pdf. Accessed September 9, 2017
   Google Scholar
• Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, control-controlled study of guanfacine extended release in children and adolescents with attention deficit/hyperactivity disorder. Pediatrics 2008;121:E73-84
   PubMed Web of Science ®Google Scholar
• Sallee F, McGough J, Wigal T, et al. on behalf of the SPD503 Study Group. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a control-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48:155-65
   PubMed Web of Science ®Google Scholar
• Alamo C, Lopez-Munoz F, Sanchez-Garcia J. Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (adhd). Actas Esp Psiquiatr 2016;44:107-12
   PubMed Web of Science ®Google Scholar
• Stuhec M. Pharmacotherapy of ADHD in Slovenia: realities and perspectives. Eur Child Adolesc Psychiatry 2016;25:455-7
   PubMed Web of Science ®Google Scholar
• Hervas A, Huss M, Johnson M, et al. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial. Eur Neuropsychopharmacol 2014;24:1861-72
   PubMed Web of Science ®Google Scholar
• Sikirica V, Findling RL, Signorovitch, et al. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology. CNS Drugs 2013;27:943-53
   PubMed Web of Science ®Google Scholar
• Signorovitch J, Erder MH, Xie J, et al. Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Pharmacoepidemiol Drug Saf 2012;21(Suppl2):S130-S7
   Web of Science ®Google Scholar
• Joseph A, Ayyagari R, Xie M, et al. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adoles Psychiatry 2017;26:875-97
   PubMed Web of Science ®Google Scholar
• Huss M, Sikirica V, Hervas A, et al. Guanfacine extended release for children and adolescents with attention-deficit/hyperactivity disorder: efficacy following prior methyphenidate treatment. Neuropsychiatr Dis Treat 2016;112:1085-101
   PubMedGoogle Scholar
• Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and meta-regression. J Am Acad Child Adolesc Psychiatry 2014;53:174-87
   PubMed Web of Science ®Google Scholar
• Culter AJ, Brams M, Bukstein O, et al. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2014;53:1092-101
   PubMed Web of Science ®Google Scholar
• Kabul S, Alatorre C, Montejano LB, et al. Real-world dosing patterns of atomoxetine in adults with attention-deficit/hyperactivity disorder. CNS Neurosci Ther 2015;21:936-42
   PubMed Web of Science ®Google Scholar
• Swensen AR, Birnbaum HG, Secnik K, et al. Attention-deficit/hyperactivity disorder: increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry 2003;42:1415-23
   PubMed Web of Science ®Google Scholar
• Chumney ECG, Simpson KN. Approaches to estimating maximum study power for economic endpoints in fixed sample size designs. ISPOR Connections 2006;12. Available online at: http://www.ispor.org/news/articles/Dec06/economic_eval.asp
   Google Scholar
• Barner JC, Khoza S, Oladapo A. ADHD medication use, adherence, persistence and cost among Texas Medicaid children. Curr Med Res Opin 2011;27(Suppl2):13-22
   Web of Science ®Google Scholar
• Christensen L, Sasane R, Hodgkins P, et al. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin 2010;26:977-89
   PubMed Web of Science ®Google Scholar
• Khoza S, Oladapo AO, Barner JC. Adherence to medication for attention deficit/hyperactivity disorder: does time frame matter? J Pharm Health Serv Res 2011;2:157-63
   Google Scholar
• Lawson KA, Johnsrud M, Hodgkins P, et al. Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program. Clin Ther 2012;34:944-56
   PubMed Web of Science ®Google Scholar
• Molife C, Bernauer MJ, Farr AM, et al. Combination therapy patterns and predictors in ADHD in commercially insured and Medicaid populations. Postgrad Med 2012;124:7-22
   PubMed Web of Science ®Google Scholar
• Pastor PN, Reuben CA. Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004–2006. Vital Health Stat 2008;10:1-14
   Google Scholar
• Pohl G, Van Brunt D, Ye W, et al. A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). BMC Health Serv Res 2009;9:95
   PubMed Web of Science ®Google Scholar
• Chernick MR. Bootstrap methods: a practitioner’s guide. New York, NY: Wiley & Sons; 1999
   Google Scholar
• Guevara J, Lozano P, Wickizer T, et al. Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:71-8
   PubMed Web of Science ®Google Scholar
• Sikirica V, Haim Erder M, Xie J, et al. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents. Pharmacoeconomics 2012;30:e1-15
   PubMedGoogle Scholar
• Erder MH, Xie J, Signorovitch JE, et al. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy 2012;10:381-95
   PubMedGoogle Scholar
• Betts KA, Sikirica V, Hodgkins P, et al. Incidence of stimulant augmentation among children and adolescents with attention/deficit hyperactivity disorder (ADHD) during 2010. Pharmacoepidemiol Drug Saf 2013;22:515
   Web of Science ®Google Scholar
• Adler LD, Nierenberg AA. Review of medication adherence in children and adolescents with ADHD. Postgrad Med 2010;122:184-91
   PubMed Web of Science ®Google Scholar
• Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder – a systematic literature review. Neuropsychiatr Dis Treat 2014;10:1543-69
   PubMed Web of Science ®Google Scholar
• Garbe E, Mikolajczyk RT, Banaschewski T, et al. Drug treatment patterns of attention-deficit/hyperactivity disorder in children and adolescents in Germany: results from a large population-based cohort study. J Child Adolesc Psychopharmacol 2012;22:452-8
   PubMed Web of Science ®Google Scholar
• Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112-20
   PubMed Web of Science ®Google Scholar
• Connor DF, Arnsten AT, Pearson GS, et al. Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents. Expert Opin Pharmacother 2014;15:1601-10
   PubMed Web of Science ®Google Scholar
• Fullerton CA, Epstein AM, Frank RG, et al. Medication use and spending trends among children with ADHD in Florida’s Medicaid program, 1996–2005. Psychiatr Serv 2012;63:115-21
   PubMed Web of Science ®Google Scholar
• Štuhec M1, Locatelli I, Švab V. Trends in attention-deficit/hyperactivity disorder consumption in children and adolescents in Slovenia from 2001 to 2012: a use study from a national perspective. J Child Adolesc Psychopharmacol 2015;25:254-9
   PubMed Web of Science ®Google Scholar
• KapvayTM [package insert] [Internet]. Atlanta, GA: Shionogi Pharma; 2010. Available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022331s001s002lbl.pdf. Accessed September 15, 2017
   Google Scholar
• Intuniv (guanfacine) [Internet]. London, UK: European Medicines Agency; 2015. Available online at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003759/human_med_001910.jsp&mid=WC0b01ac058001d124. Accessed October 13, 2017
   Google Scholar